UPDATE 1-BioMarin says FDA to delay deciding on approval of DMD drug

Dec 18 (Reuters) - Drug developer BioMarin Pharmaceutical Inc said the U.S. Food and Drug Administration told the company that it would not be able to decide on the marketing approval of its lead drug as scheduled, the second setback for the company.